ROS1 and neoplasm: Several studies have shown that in NSCLC cells with gene alterations of KRAS G12C, BRAF V600E, EGFR, ALK, or ROS1, dysregulation of the Hippo pathway decreases the initial response to various tyrosine kinase inhibitors, which is associated with resistance of targeted therapy and tumor recurrence.